Kirkland & Ellis advised Eli Lilly & Company (NYSE: LLY) in connection with a $500 million venture capital fund partnership with Andreessen Horowitz. The fund will invest in companies at all stages, from company creation to growth, to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies. Beyond contributing all the capital, Lilly will have the ability to provide additional resources to the underlying portfolio companies, including Catalyze360, a specialized support structure for biotech startups that includes Lilly Ventures, Lilly Gateway Labs and Lilly ExplorR&D — all of which provide biotech startups with access to world-class pre-clinical and clinical drug development talent and resources.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
